SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-001306
Filing Date
2022-01-14
Accepted
2022-01-14 17:13:52
Documents
13
Period of Report
2022-01-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 33934
2 form8-k_001.jpg GRAPHIC 5687
  Complete submission text file 0001493152-22-001306.txt   221985

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lpcn-20220114.xsd EX-101.SCH 3033
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lpcn-20220114_lab.xml EX-101.LAB 34476
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lpcn-20220114_pre.xml EX-101.PRE 22595
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3607
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 22532653
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences